-transparent.png){kind=logo}
The pharmacokinetics and pharmacodynamics of propranolol (80 mg by mouth) were studied in seven extensive and four poor metabolisers of debrisoquine. Evidence for impairment of the 4'-hydroxylation of propranolol was found in poor metabolisers. However, no significant difference was detected in the oral clearance of unchanged drug between the two groups of debrisoquine oxidation phenotypes. Poor metabolisers of debrisoquine did not experience more intense or more prolonged beta-adrenoceptor blockade than extensive metabolisers of debrisoquine.
Related Publications
M S Lennard, and
P R Jackson, and
S Freestone, and
G T Tucker, and
L E Ramsay, and
H F Woods
January 1990,
European journal of clinical pharmacology,
M S Lennard, and
P R Jackson, and
S Freestone, and
G T Tucker, and
L E Ramsay, and
H F Woods
November 1991,
British journal of clinical pharmacology,
M S Lennard, and
P R Jackson, and
S Freestone, and
G T Tucker, and
L E Ramsay, and
H F Woods
February 1988,
British journal of clinical pharmacology,
M S Lennard, and
P R Jackson, and
S Freestone, and
G T Tucker, and
L E Ramsay, and
H F Woods
January 1987,
European journal of clinical pharmacology,
M S Lennard, and
P R Jackson, and
S Freestone, and
G T Tucker, and
L E Ramsay, and
H F Woods
March 1991,
The Journal of pharmacology and experimental therapeutics,
M S Lennard, and
P R Jackson, and
S Freestone, and
G T Tucker, and
L E Ramsay, and
H F Woods
January 1987,
Clinical pharmacokinetics,
M S Lennard, and
P R Jackson, and
S Freestone, and
G T Tucker, and
L E Ramsay, and
H F Woods
September 1976,
Clinical pharmacology and therapeutics,
M S Lennard, and
P R Jackson, and
S Freestone, and
G T Tucker, and
L E Ramsay, and
H F Woods
January 1989,
Psychopharmacology series,
M S Lennard, and
P R Jackson, and
S Freestone, and
G T Tucker, and
L E Ramsay, and
H F Woods
January 1991,
European journal of clinical pharmacology,
M S Lennard, and
P R Jackson, and
S Freestone, and
G T Tucker, and
L E Ramsay, and
H F Woods
May 1989,
British journal of clinical pharmacology,
